Update on osteoporosis in men

Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):759-772. doi: 10.1016/j.beem.2018.05.007. Epub 2018 May 26.

Abstract

Osteoporosis in men remains under-diagnosed and under-appreciated. After a low trauma fracture, a man is less likely to have evaluation and treatment. The lifetime risk for osteoporotic fracture in older men may range from 13 to 25%, and as men live longer, there will be more fractures. Newer strategies for determining which men should have bone density testing are emerging. Information from observational studies are providing insights that allow targeted testing and treatment of those men at the highest risk for fracture. Treatment with most of the same medications used in women is efficacious and generally safe. Nonetheless, the fear of side effects of treatments for an asymptomatic disorder (before a fracture) and other barriers have made management challenging in men at risk for fracture. This review provides updates on epidemiology, pathophysiology, evaluation and treatment of male osteoporosis.

Keywords: bisphosphonates; denosumab; fracture; men; osteoporosis; teriparatide.

Publication types

  • Review

MeSH terms

  • Bone Density / drug effects
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use
  • Humans
  • Male
  • Observational Studies as Topic / statistics & numerical data
  • Osteoporosis* / diagnosis
  • Osteoporosis* / drug therapy
  • Osteoporosis* / epidemiology
  • Osteoporosis* / therapy
  • Osteoporotic Fractures / epidemiology
  • Osteoporotic Fractures / prevention & control
  • Sex Factors

Substances

  • Bone Density Conservation Agents